LOS ANGELES--(BUSINESS WIRE)--Moraga Biotechnology Corporation, an adult stem cell company based in Culver City, California, announces the publication of its blood-derived Blastomere-Like Stem Cells (BLSCs) patent with the European Patent Office (EPO). The EPO had previously granted the patent of the Company’s “non-embryonic totipotent blastomere-like stem cell” on May 19, 2011 in which the English claims were erroneously limited to rat stem cells. This error was corrected in the republished EP17895540B9. The EP17895540B9 claims isolated mammal/human post-natal blastomere-like stem cells and isolation methods.
Moraga’s chief executive, Dr. John F. Wong, noted: “We are very pleased to have the EPO grant the ‘540’ patent as Moraga and its U.K. partner, Pharmacells, Ltd. achieved a major milestone validating its adult stem cell technology. Moraga is particularly indebted to its patent counsel, Fish and Associates (Irvine, CA) for its fine work in prosecuting its patents both in Europe and currently in the United States with the U.S. Patent and Trade Office (USPTO).”
For more information on Moraga Biotechnology Corp. please visit www.moragabiotech.com.